![]() | |
Clinical data | |
---|---|
Trade names | Perfan |
AHFS/Drugs.com | International Drug Names |
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 50% (oral) |
Protein binding | 85% |
Metabolism | Liver (oxidation) |
Elimination half-life | 4 to 10 hours |
Excretion | Renal (60 to 70%) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C12H12N2O2S |
Molar mass | 248.30 g·mol−1 |
3D model (JSmol) | |
Melting point | 255 to 258 °C (491 to 496 °F) (decomposes) |
| |
| |
(verify) |
Enoximone (INN, trade name Perfan) is an imidazole phosphodiesterase inhibitor. It is used in the treatment of congestive heart failure and is selective for phosphodiesterase 3.[1]
References
[edit]External links
[edit]Media related to Enoximone at Wikimedia Commons